BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop ...

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

BioXcel Therapeutics (BTAI) announced that it will effect a 1-for-16 reverse stock split of its common stock. The reverse stock split will ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company with a market capitalization of $14.83 million, announced today the implementation of a 1-for-16 reverse stock split of its common ...

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial ...

Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

BioXcel Therapeutics, Inc. conducted a special meeting of stockholders to decide on crucial matters. The meeting saw the ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company specializing in drug development with a current market capitalization of $17.2 million, announced on Wednesday the expansion of ...

Three C-level officials at New Haven-based biopharmaceutical company BioXcel Therapeutics Inc. have taken cuts to their cash compensation as the business, which uses artificial intelligence to ...